Back

Solstice Oncology launches with $225 million financing for porustobart trial

Verifying
  • Solstice Oncology launched with a $225 million Series A financing to advance porustobart.
  • Porustobart produced a 30% objective response rate in 7 of 23 patients.
  • Enrollment for the MSS stage II-III colon cancer Phase 2 trial starts early Q4 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.